Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

saccharomyces boulardii

What does the research say about saccharomyces boulardii?

9 health outcomes synthesised

Research on Saccharomyces boulardii covers 9 health outcomes, with the strongest evidence focused on reducing diarrhea rates. Across two separate syntheses totaling 18 studies, high-strength evidence shows moderate effects in clinical populations such as children with acute diarrhea and patients undergoing Helicobacter pylori eradication therapy. Doses in these studies ranged from 250 mg/day to 500 mg four times daily, though reporting was inconsistent.

Strongest evidence

  • Reduced Diarrhea Rate (9 studies, high evidence strength): 7 of 9 studies reported beneficial effects with a moderate effect size, primarily in children with acute diarrhea or H. pylori infection. Doses ranged from 250 mg to 1000 mg per day. Two neutral studies suggest benefit may not be universal.
  • Reduced Diarrhea (9 studies, high evidence strength): All 9 studies found benefit, with moderate effect sizes in clinical populations including H. pylori patients, pelvic radiotherapy patients, and hospitalized patients. Effective dose: 250 mg/day to 500 mg four times daily, median study duration 14 days.
  • Improved H Pylori Eradication Rates (7 studies, high evidence strength): 5 of 7 studies showed small beneficial effects (risk ratios ~1.09–1.14). Effective dose: 250 mg twice daily for 14 days. Two neutral studies may lack power.

Mixed or weaker evidence

  • Increased H. pylori Eradication Rate (5 studies, moderate evidence): 4 of 5 studies found small-to-moderate benefit; one meta-analysis gave a 12% relative improvement. Dosing inconsistently reported.
  • Reduced Abdominal Pain (5 studies, moderate evidence): 4 studies beneficial with mixed effect sizes; a 2025 meta-analysis found no significant reduction in abdominal pain.
  • Reduced Duration of Diarrhea (4 studies, moderate evidence): 3 of 4 studies reported small-to-moderate benefit in children with acute diarrhea.
  • Reduced Constipation (3 studies, moderate evidence): All 3 studies showed large effects (risk ratios 0.35–0.38) in H. pylori patients, but evidence is preliminary.
  • Reduced Abdominal Distension (3 studies, low evidence): All studies found moderate-to-large benefit, primarily in children with H. pylori.
  • Reduced Stool Frequency (3 studies, low evidence): All 3 studies found moderate benefit in children with acute diarrhea, dose 250 mg twice daily.

Effective dose patterns Common doses across outcomes cluster at 250 mg twice daily or 250–1000 mg per day. However, most studies did not consistently report dose or form, limiting precise recommendations from the evidence.

Population insights Pediatric populations dominated research on diarrhea and stool frequency, while H. pylori-infected patients (children and adults) were the most studied for eradication and abdominal symptoms. Generalizability to healthy individuals or other contexts is uncertain.

Notable caveats Publication bias is a concern across many outcomes, as null-result studies are less likely to be published. Study durations were often short (14 days median) and dosing information incomplete. Several syntheses note that small sample sizes in neutral studies may have limited power to detect benefit.

Frequently asked

  • What is Saccharomyces boulardii good for according to research?
    Research syntheses covering 9 health outcomes show strongest evidence for reducing diarrhea rates: 7 of 9 studies found benefit in children with acute diarrhea and H. pylori patients, and 9 of 9 studies found benefit for reducing diarrhea in clinical populations such as hospitalized patients. Moderate evidence supports small benefits for H. pylori eradication and abdominal pain reduction.
  • What dose of Saccharomyces boulardii is typically used in studies?
    The most commonly reported doses are 250 mg twice daily (for H. pylori eradication and stool frequency) and 250 mg to 500 mg four times daily for reducing diarrhea. However, dosing was inconsistently reported across studies, with many not specifying the form or duration, so the evidence does not support a single optimal dose.
  • Who benefits most from Saccharomyces boulardii?
    The research predominantly focuses on children with acute diarrhea and patients with Helicobacter pylori infection (both children and adults). Patients undergoing antibiotic treatment or pelvic radiotherapy also showed benefit. Generalizability to healthy individuals is uncertain.
  • Are there caveats or limitations in the research on Saccharomyces boulardii?
    Yes. Publication bias is a concern—null-result studies are less likely to be published. Many studies had short durations (median 14 days), small sample sizes in neutral studies, and inconsistent reporting of doses and supplement forms. Evidence for constipation, abdominal distension, and stool frequency is preliminary (only 3 studies each).
  • Does Saccharomyces boulardii help with H. pylori eradication?
    High-strength evidence from 7 studies shows a small but consistent benefit (risk ratios 1.09–1.14) when used as an adjunct to standard triple therapy. The effective dose was 250 mg twice daily for 14 days, though dosing was infrequently reported. Two neutral studies may have lacked power to detect benefit.
  • Does Saccharomyces boulardii help with constipation?
    Three studies in H. pylori patients all reported large beneficial effects (risk ratios 0.35–0.38). However, the evidence base is small and considered preliminary. No consistent dose or study duration data were available, and generalizability to other populations is uncertain.
    Back to top